ドロップダウンアイコン
ドロップダウンアイコン
ドロップダウンアイコン
ドロップダウンアイコン
JP
/
EN
メニューアイコン
Research
Craif Now Runs Joint Research at More Than 50 Institutions in Japan, Including University Hospitals and National Cancer Center Hospitals
2025.07.03

Named partners include the University of Tokyo Hospital, Keio University Hospital, and both National Cancer Center hospitals.

TOKYO, July 2, 2025 - Craif Inc., a bio-AI company developing a urine analysis platform for early detection of cancer and other diseases, said today that the number of institutions conducting joint research with the company has passed 50.

Craif's platform, which the company calls its bio-AI technology platform, pairs advanced analysis of nucleic acids in urine, microRNA above all, with AI. Most partner institutions are university hospitals and cancer centers, spread across Japan. Craif says the aim is to detect cancer and other diseases at a very early stage and match treatment more closely to the individual patient.

Participating institutions include:

  • Asahikawa Medical University Hospital
  • Iwate Medical University Hospital
  • Kagoshima University Hospital
  • Kawasaki Medical School Hospital
  • The Cancer Institute Hospital of JFCR, Ariake
  • Kyushu Cancer Center
  • Kyushu University Beppu Hospital
  • Gifu University Hospital
  • Kurume University Hospital
  • Keio University Hospital
  • National Cancer Center Hospital, Tsukiji
  • National Cancer Center Hospital East
  • Shikoku Cancer Center, National Hospital Organization
  • Saitama Medical University Hospital
  • Juntendo University Hospital
  • Chiba University Hospital
  • Institute of Science Tokyo Hospital
  • Tokyo Medical University Hospital
  • The Jikei University Hospital
  • Tokyo Women's Medical University
  • The University of Tokyo Hospital
  • Nagoya University Hospital
  • Hirosaki University Hospital
  • Fujita Health University Hospital
  • Hokkaido University Hospital
  • Wakayama Medical University Hospital
  • More than 30 additional institutions

What the research covers

For the cancers and brain tumors below, the scope includes how disease begins and progresses, the development of early screening technology, and, for some cancer types, predicting how well molecular targeted drugs will work.

  • Cancer, including pancreatic, gastric, colorectal, esophageal, lung, breast, ovarian, urothelial, kidney, prostate, liver, gallbladder and bile duct, cervical, endometrial, and head and neck cancers, and hematologic malignancies, among others
  • Brain tumors
  • Spinal muscular atrophy, SMA: This scope is narrower, with the development of early screening technology only.

How Craif runs the work

Craif updates its AI models regularly to improve analytical accuracy over time. Each study applies one quality management protocol from sample preprocessing through analysis, which the company says enables reproducible, reliable data. Craif continues to make results public through presentations at conferences in Japan and abroad and through manuscripts submitted to journals. Evidence from some of these studies feeds the development and improvement of the miSignal series, and Craif says it intends to widen adoption from there.

About the miSignal series

The miSignal series is a set of cancer risk tests aimed at prevention and early detection. It has four parts: miSignal Scan, which assesses cancer risk through microRNA analysis combined with AI; miSignal Lite, a simpler cancer risk assessment; miSignal Navi, a genetic test focused on cancer; and miSignal Check, which monitors DNA damage to aid prevention.

All four need only a urine or saliva sample, so collection places no physical burden on the person tested. Craif presents the four together as one route: understand your constitutional risk, monitor day-to-day DNA damage to support prevention, and catch at an early stage the cancer that prevention does not stop. More information: https://misignal.jp/

Regulatory statement, Japan

The miSignal series is not a medical device. It judges risk by statistical calculation on analyzed data. It does not take the place of a medical diagnosis of whether a person has cancer, and a result judged low risk does not mean that cancer is absent or that the person will not develop cancer in the future.

About Craif

Craif is a bio-AI company founded in 2018 that develops non-invasive tests for the early detection of cancer. Its platform combines proprietary biomarker detection from urine and other bodily fluids with AI to assess disease risk. Building on one of the world's largest urine datasets, Craif aims to create a urine analysis platform that detects a wide range of diseases early, with cancer as the first step. The company is based in Tokyo and operates a wholly owned laboratory in San Diego, opened in 2026. Learn more at craif.com.

Media contact

press_us@craif.com